ClinicalTrials.gg
Not yet recruitingNCT07661212Updated Jun 22, 2026

Timing of Serratus Anterior Plane Block in Mastectomy Surgery

An interventional study of Ultrasound-Guided Serratus Anterior Plane Block and Bupivacaine in Quality of Recovery After Mastectomy, Serratus Anterior Plane Block and Postoperative Pain, sponsored by Bakirkoy Dr. Sadi Konuk Research and Training Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Bakirkoy Dr. Sadi Konuk Research and Training Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Postoperative pain following mastectomy may adversely affect early mobilization, patient comfort, and overall quality of recovery. Serratus anterior plane block is an ultrasound-guided regional anesthesia technique that provides analgesia to the anterolateral thoracic wall and is increasingly used as part of multimodal analgesia for breast surgery. Although the analgesic efficacy of serratus anterior plane block has been investigated in breast surgery, the clinical impact of the timing of block administration remains insufficiently defined.

This prospective, randomized, controlled, patient and assessor blinded clinical trial will compare two different timings of ultrasound-guided serratus anterior plane block in adult female patients undergoing elective unilateral mastectomy under general anesthesia. Participants will be randomized to receive serratus anterior plane block either after induction of general anesthesia and before surgical incision, or after completion of surgery and before extubation. In both groups, the block will be performed under ultrasound guidance using 25 mL of 0.25% bupivacaine.

The primary outcome is postoperative quality of recovery at 24 hours, assessed using the Quality of Recovery-15 questionnaire. Secondary outcomes include postoperative pain scores at predefined time points during the first 24 postoperative hours, intraoperative remifentanil consumption, postoperative opioid and non-opioid analgesic requirements, time to first analgesic requirement, postoperative nausea and vomiting, length of hospital stay, complications, inflammatory response markers including CRP and neutrophil-to-lymphocyte ratio, and intraoperative hemodynamic variables.

The study is planned to enroll 80 participants at a single tertiary training and research hospital. The findings are expected to clarify whether preincisional administration of serratus anterior plane block provides superior postoperative recovery, analgesic efficacy, and modulation of inflammatory response compared with administration at the end of surgery.

02

Conditions studied

  • Quality of Recovery After Mastectomy
  • Serratus Anterior Plane Block
  • Postoperative Pain
  • Mastectomy

Keywords

  • Serratus Anterior Plane Block
  • Postoperative Pain
  • Mastectomy
  • Regional Anesthesia
  • Pain Management
  • Bupivacaine
  • Quality of Recovery
  • CRP
  • Neutrophil-Lymphocyte Ratio
  • Inflammation
  • Breast Surgery
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's planned enrollment of 80 is close to the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Bakirkoy Dr. Sadi Konuk Research and Training Hospital is the lead sponsor of 122 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 years or older
  • Scheduled for elective unilateral mastectomy surgery
  • Planned to undergo surgery under general anesthesia
  • physical status I-III
  • Willing and able to participate in the study
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
  • Known allergy to local anesthetics planned for use in the study
  • Chronic opioid use
  • Current or therapy
  • Presence of chronic inflammatory disease
  • Surgical duration shorter than 30 minutes
  • Active infection
  • Coagulopathy
  • Infection at the planned block site
  • Pregnancy or lactation
  • Advanced hepatic failure or advanced renal failure
  • Reoperation due to recurrent disease
  • Inability to communicate adequately or to provide reliable pain scores
  • Psychiatric or neurological condition limiting reliable completion of the QoR-15 questionnaire or Numeric Rating Scale assessments
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Preincisional SAP Block

    Participants assigned to this arm will receive ultrasound-guided serratus anterior plane block after induction of general anesthesia and before surgical incision. The block will be performed on the operative side using 25 mL of 0.25% bupivacaine, in addition to standardized general anesthesia and postoperative analgesic management.

    Procedure: Ultrasound-Guided Serratus Anterior Plane Block · Drug: Bupivacaine

  • Experimental
    End-of-Surgery SAP Block

    Participants assigned to this arm will receive ultrasound-guided serratus anterior plane block after completion of surgery and before extubation. The block will be performed on the operative side using 25 mL of 0.25% bupivacaine, in addition to standardized general anesthesia and postoperative analgesic management.

    Procedure: Ultrasound-Guided Serratus Anterior Plane Block · Drug: Bupivacaine

Interventions

  • ProcedureUltrasound-Guided Serratus Anterior Plane Block

    Ultrasound-guided serratus anterior plane block will be performed under general anesthesia on the operative side. With the patient in the supine position and the ipsilateral arm abducted, a high-frequency linear ultrasound probe will be placed at the midaxillary line around the fourth to fifth intercostal level. After identification of the latissimus dorsi and serratus anterior muscles, the block needle will be advanced using an in-plane technique, and 25 mL of 0.25% bupivacaine will be injected into the fascial plane between these muscles after negative aspiration. In the preincisional arm, the block will be performed after induction of general anesthesia and before surgical incision. In the end-of-surgery arm, the same block will be performed after completion of surgery and before extubation.

    Also known as: SAP Block

  • Bupivacaine 0.25%, 25 mL (62.5 mg), will be administered as a single ultrasound-guided injection into the serratus anterior plane on the operative side. In the preincisional arm, administration will occur after induction of general anesthesia and before surgical incision. In the end-of-surgery arm, administration will occur after completion of surgery and before extubation.

06

What researchers measure

Primary outcomes

  1. Postoperative Quality of Recovery at 24 Hours

    Postoperative quality of recovery will be assessed using the Quality of Recovery-15 questionnaire. The postoperative 24-hour QoR-15 score will be compared between the preincisional serratus anterior plane block group and the end-of-surgery serratus anterior plane block group. Higher scores indicate better quality of recovery.

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Resting Postoperative Pain Scores

    Resting pain intensity will be assessed using the Numeric Rating Scale at postoperative 0, 1, 4, 8, 12, 16, 20, and 24 hours.

    Time frame: Postoperative 0 to 24 hours

  2. Intraoperative Remifentanil Consumption

    Total intraoperative remifentanil consumption will be recorded and compared between groups.

    Time frame: During surgery

  3. Postoperative Opioid Consumption

    Total opioid consumption during the first 24 postoperative hours will be calculated based on tramadol use.

    Time frame: Postoperative 0 to 24 hours

  4. Postoperative Non-Opioid Analgesic Consumption

    Total non-opioid analgesic consumption during the first 24 postoperative hours will be recorded, including paracetamol use.

    Time frame: Postoperative 0 to 24 hours

  5. Time to First Analgesic Requirement

    The time from admission to the postoperative recovery unit to the first requirement for rescue analgesia will be recorded.

    Time frame: Postoperative 0 to 24 hours

  6. Postoperative Nausea and Vomiting

    The occurrence of postoperative nausea and vomiting will be assessed during the first 24 postoperative hours.

    Time frame: Postoperative 0 to 24 hours

  7. Length of Hospital Stay

    Length of hospital stay will be recorded as the number of days from surgery to discharge.

    Time frame: From surgery until hospital discharge, assessed up to 30 days.

  8. C-Reactive Protein Level

    Serum C-reactive protein concentration will be measured as a marker of postoperative inflammatory response and reported in mg/L.

    Time frame: Postoperative 6 hours

  9. White Blood Cell Count

    Absolute neutrophil count will be measured from the complete blood count and reported in ×10\^9/L.

    Time frame: Postoperative 6 hours

  10. Absolute Neutrophil Count

    Absolute neutrophil count will be measured from the complete blood count and reported in ×10\^9/L.

    Time frame: Postoperative 6 hours

  11. Absolute Lymphocyte Count

    Absolute lymphocyte count will be measured from the complete blood count and reported in ×10\^9/L.

    Time frame: Postoperative 6 hours

  12. Neutrophil-to-Lymphocyte Ratio

    The neutrophil-to-lymphocyte ratio will be calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The ratio is unitless.

    Time frame: Postoperative 6 hours

  13. Intraoperative Heart Rate

    Heart rate will be recorded in beats per minute during the intraoperative period and compared between groups.

    Time frame: From induction of general anesthesia to completion of surgery

  14. Intraoperative Mean Arterial Pressure

    Mean arterial pressure will be recorded in mmHg during the intraoperative period and compared between groups.

    Time frame: From induction of general anesthesia to completion of surgery

07

Study locations

1 site
08

References and documents

Publications

  • Wang S, Shi J, Dai Y, Zhang J, Liu Q, Yang P, Zhu N. The effect of different nerve block strategies on the quality of post-operative recovery in breast cancer patients: A randomized controlled study. Eur J Pain. 2024 Jan;28(1):166-173. doi: 10.1002/ejp.2178. Epub 2023 Sep 1. PubMed 37655864 ↗
  • Yao Y, Li J, Hu H, Xu T, Chen Y. Ultrasound-guided serratus plane block enhances pain relief and quality of recovery after breast cancer surgery: A randomised controlled trial. Eur J Anaesthesiol. 2019 Jun;36(6):436-441. doi: 10.1097/EJA.0000000000001004. PubMed 31021882 ↗
  • Elsabeeny WY, Shehab NN, Wadod MA, Elkady MA. Perioperative Analgesic Modalities for Breast Cancer Surgeries: A Prospective Randomized Controlled Trial. J Pain Res. 2020 Nov 12;13:2885-2894. doi: 10.2147/JPR.S274808. eCollection 2020. PubMed 33209056 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07661212
Responsible party
Fatma Cigdem Ozakin (Principal Investigator, Bakirkoy Dr. Sadi Konuk Research and Training Hospital) — Principal investigator
First posted
Jun 22, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Jun 22, 2026

Study contacts

Fatma Çiğdem ÖZAKIN, MD
Contact
f.cigdemulus@gmail.com
+905464168250
Fatma Çiğdem ÖZAKIN, MD
principal investigator · Bakirkoy Dr. Sadi Konuk Research and Training Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion